talis (neuter tale); third declension; latin
distinguished; great; excellent
Why we’re here
What we’re striving for
The change we’re bringing
An appropriate treatment plan can be selected and started to stop disease progression and, as the COVID-19 pandemic demonstrated, rapid diagnosis can identify individuals who may need to quarantine to prevent widespread transmission of the disease.
Current infectious disease diagnosis technology is not geared for rapid delivery of results. Many molecular diagnostic tests are complex and time-consuming to execute and must be performed in a central lab. This can delay diagnosis for days.
Talis believed there had to be a better way.
By carefully analyzing the molecular diagnostic testing workflow and understanding which steps were critical for enabling the maximum amount of accuracy for infections disease identification, the team at Talis is developing a highly robust infectious disease testing solution–The Talis One.
Delivering the accuracy and quality of a central lab molecular diagnostic test at the time and place where it’s needed most–the doctor’s office–our company is ready to change the way we diagnose infectious disease with Talis One.
The Talis Team
Board of Directors
Felix Baker, Ph.D. has served as a member of our board of directors since June 2013. Dr. Baker is a Managing Member and Co-Founder of Baker Bros. Advisors LP, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Dr. Baker has served on the board of directors of Seagen, Inc. (previously Seattle Genetics, Inc.) since July 2003, Kodiak Sciences, Inc. since September 2015, Kiniksa Pharmaceuticals, Ltd. since October 2015 and IGM Biosciences, Inc. since January 2021. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.
Raymond Cheong, M.D., Ph.D. has served on our board of directors since June 2020. Dr. Cheong is a Principal at Baker Bros., where he has worked since 2013. Dr. Cheong has also served on the board of directors of Istari Oncology, Inc., a biotechnology company focused on immuno-oncology and immunotherapy platforms, since December 2018. Dr. Cheong received a B.S. in Chemical Engineering from the University of Maryland, College Park, and an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University, where he was awarded the Michael A. Shanoff Award for best thesis research.
Melissa Gilliam, M.D., M.P.H. has served on our board of directors since December 2020. She is a highly accomplished physician and research scientist with an academic background rooted in the humanities and a lifelong dedication to service. Dr. Gilliam is the executive vice president and provost at The Ohio State University. In this role, she is the chief academic officer of one of the largest and most comprehensive universities in the country. Prior to joining The Ohio State University, Melissa Gilliam was the Ellen H. Block Distinguished Service Professor of Health Justice and Vice Provost. She has taught as a Professor of Obstetrics and Gynecology and Pediatrics since 2005. Dr. Gilliam is also the founder and Director of the University of Chicago’s Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive Health, which conducts research to improve the health, education and wellbeing of adolescents. Prior to joining the University of Chicago, Dr. Gilliam was an Assistant Professor of Obstetrics and Gynecology at the University of Illinois at Chicago, where she also served as Adjunct Faculty to the Division of Epidemiology and Biostatistics in the School of Public Health. Dr. Gilliam received a B.A. in English from Yale University, an M.A. in Philosophy and Politics from the University of Oxford, an M.D. from Harvard Medical School and an M.P.H. in Epidemiology and Biostatistics from the University of Illinois at Chicago. She is a member of the National Academy of Medicine.
Jeryl “Jeri” Hilleman has served as a member of our board of directors since March 2021. Ms. Hilleman currently serves as Chairman of the board of Omada Health and is a Director of SI-Bone since December 2019, Novocure since July 2018, and Minerva Neurosciences since July 2018. Prior to her decision to focus on board responsibilities full time in 2020, Ms. Hilleman served as a life sciences executive and Chief Financial Officer for more than 20 years at multiple public companies, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel. Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School of the University of Pennsylvania. She is a member of the 1999 class of Henry Crown Fellow and the Aspen Global Leadership Network at the Aspen Institute.
Rustem F. Ismagilov, Ph.D. is one of our co-founders and has served on our board of directors since June 2013. Dr. Ismagilov is a Professor of Chemistry and Chemical Engineering and the Director of the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology, where he has been employed since July 2011. From July 2001 to June 2011, Dr. Ismagilov held various positions of increasing responsibility at the University of Chicago, including as a Professor in the Department of Chemistry. Dr. Ismagilov received a B.S. from the Russian Academy of Sciences and a Ph.D. from the University of Wisconsin, Madison and completed postdoctoral training at Harvard.
Matthew L. Posard has served on our board of directors since March 2016. Mr. Posard is a Founding Principal at Explore-DNA, Inc., a life sciences and diagnostics consulting firm, a position he has held since March 2016. Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc. from February 2017 to April 2018 and as Executive Vice President and Chief Commercial Officer of Cardiff from March 2015 to May 2016. Mr. Posard also held various executive roles at Illumina from February 2006 to February 2015, including most recently as Senior Vice President, General Manager of New and Emerging Markets. Mr. Posard serves as Chairman of Nautilus Biotechnology, Inc. since January 2019, Stemson Therapeutics, LLC since March 2019, and DermTech, Inc. since July 2016. Mr. Posard also serves on the board of directors of Halozyme Therapeutics, Inc. since March 2013. Mr. Posard received a B.A. in Management Science from the University of California, San Diego.
Randal Scott, Ph.D. has served on our board of directors since February 2016. Dr. Scott is a co-founder and Chairman of the board of directors of Genome Medical, Inc., a genomic medicine company founded in August 2016. Previously, Dr. Scott was a co-founder of Invitae Corporation where he served as Chairman of the board of directors and Chief Executive Officer from August 2012 to January 2017 and Executive Chairman from January 2017 to August 2019. Prior to Invitae, Dr. Scott co-founded Genomic Health, where he served as Chairman of the board of directors and Chief Executive Officer from August 2000 to 2009 and Executive Chairman from 2009 to August 2012. Dr. Scott has also served on the board of directors of BridgeBio Pharma, Inc. since June 2020 and Freenome Holdings, Inc. since December 2017. Dr. Scott received a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
Scientific Advisory Board
Rustem Ismagilov, Ph.D., Chair
Walter Koch, Ph.D.
Jane Schwebke, M.D.
Excellence is what we stand for. Literally. It’s not just that Talis is actually the Latin word for “excellent”, it is also our mission to deliver excellence in the field of point-of-care diagnostics. We strive to improve healthcare for all through purpose-driven, accessible diagnostic solutions—so healthcare professionals can make improved treatment decisions for infectious diseases and provide peace of mind for patients.